X

Genitourinary Cancer

Genitourinary Cancer

ctDNA Identifies Patients Who Benefit From Immunotherapy in MIUC

Among patients with muscle-invasive urothelial carcinoma, the presence of detectable ctDNA after surgery may identify those likely to benefit from adjuvant immunotherapy with the ICI atezolizumab.<

Medscape
07/14/2021
Reducing Immunotherapy Resistance in Prostate Tumors

Reprogramming immune cells inside tissues surrounding prostate tumors may improve response to checkpoint inhibitor therapy in patients, according to a new study.

Oncology Times - Latest Articles
07/05/2021
Adjuvant Radiation May Provide a Survival Benefit Over Salvage Radiation in High-Risk Prostate Cancer

Adjuvant RT after radical prostatectomy may offer greater benefit than early salvage RT in men with high-risk prostate cancer, according to results of a study published in the Journal of Clinical..

Cancer Therapy Advisor
07/01/2021

Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death

Investigators evaluate the impact of adjuvant versus early sRT on all-cause mortality risk in men with adverse pathology defined as positive pelvic lymph nodes or pGleason score 8-10 prostate cance

Journal of Clinical Oncology
06/04/2021
Construction and Validation of a Novel Eight-Gene Risk Signature to Predict the Progression and Prognosis of Bladder Cancer

Study investigators establish a novel eight-gene risk signature that could predict the progression and prognoses of bladder cancer patients.

Frontiers in Oncology
06/29/2021
How to Avoid Cystectomy in Muscle-Invasive Bladder Cancer

New data show that a large subset of patients with muscle-invasive bladder cancer can avoid cystectomy and enjoy long-term, bladder-intact, disease-free survival.

Medscape
06/08/2021
No Survival Difference for Front-Line Combination Regimens in Intermediate- and Poor-Risk Clear Cell RCC: Real-World Outcomes

A large retrospective study of real-world patients with RCC shows similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they are treated with the comb

The ASCO Post
06/07/2021
Can Smoking Cause Differences in Urine Microbiome in Male Patients With Bladder Cancer? A Retrospective Study

Study investigators explore the composition of male urinary microbiome and the correlation between tobacco smoking and microbiome in this study.

Frontiers in Oncology
06/08/2021
Adjuvant Immunotherapy Benefit in Resected Kidney Cancer

For patients with high-risk clear-cell renal carcinoma who had undergone surgery, DFS is significantly longer if they received adjuvant pembrolizumab compared with placebo.

Medscape
06/03/2021
FDA Approves Piflufolastat F-18 Injection, a PSMA PET Imaging Agent, for the Detection of Metastatic or Recurrent Prostate Cancer

The FDA approves piflufolastat F-18 injection, an F-18–labeled PSMA-targeted positron-emission tomography imaging agent, to identify suspected metastasis or recurrence of prostate cancer.

The ASCO Post
05/27/2021
Identification of an m6A-Related lncRNA Signature for Predicting the Prognosis in Patients With Kidney Renal Clear Cell Carcinoma

This study aims to construct an m6A-related long non-coding RNAs signature to accurately predict the prognosis of kidney clear cell carcinoma patients using data obtained from...

Frontiers in Oncology
05/26/2021
Enfortumab Vedotin-ejfv After PD-1 or PD-L1 Inhibitor Therapy for Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma

This study shows a high response rate with the nectin-4–directed antibody-drug conjugate enfortumab vedotin-ejfv in cisplatin-ineligible patients with advanced or metastatic urothelial carcinoma...

The ASCO Post
05/24/2021
'Very Strong Statement' to Discuss PSA Screens With Younger AAs

Might more PSA testing in younger African American men (40-55 years old) be a key to reducing their relatively high mortality rates from prostate cancer compared to same-aged White men?

Medscape
05/19/2021
Sacituzumab Govitecan-hziy for Patients With Pretreated Metastatic Urothelial Carcinoma

This study finds that the antibody-drug conjugate sacituzumab govitecan-hziy produces responses in patients with metastatic urothelial carcinoma progressing after platinum-based CT and...

The ASCO Post
05/18/2021
Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Study investigators perform a comprehensive evaluation of the immunological changes in mCRPC patients by phenotyping the peripheral blood mononuclear cells during radium-223 therapy.

Frontiers in Oncology
05/18/2021
PD-1-Positive Tumor-Associated Macrophages Define Poor Clinical Outcomes in Patients With Muscle Invasive Bladder Cancer Through Potential CD68/PD-1 Complex Interactions

Results show that PD-1-positive TAMs can be a negative survival indicator in patients with muscle-invasive bladder cancer, and that the mechanistic effects could result due to a combination of PD-1

Frontiers in Oncology
05/17/2021
Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Patients with mUC who progress on platinum-based combination chemotherapy and CPIs have limited options that offer objective response rates of approximately 10% with a median OS of 7-8 months.

Journal of Clinical Oncology
04/30/2021
Second-Line FOLFOX Chemotherapy versus Active Symptom Control for Advanced Biliary Tract Cancer

The aim of this study is to determine the benefit derived from second-line FOLFOX chemotherapy in advanced biliary tract cancer.

The Lancet Oncology
05/01/2021
Healthy Lifestyle May Offset Genetic Risk in Prostate Cancer

Adhering to a healthy lifestyle may offset the heightened risk of lethal prostate cancer in patients with adverse genetic risk factors, according to results of a large U.S. study.

Medscape
04/15/2021
Relugolix As First Oral GnRH Antagonist Option for Prostate Cancer

The FDA recently approved relugolix, a GnRH receptor antagonist, for adults with advanced prostate cancer.

Oncology Times - Latest Articles
04/05/2021
Relugolix As First Oral GnRH Antagonist Option for Prostate Cancer

The FDA recently approved relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, for adults with advanced prostate cancer. 

Oncology Times - Latest Articles
04/05/2021
Seminal Vesicle-Sparing in Radical Cystectomy Shown to Improve Outcomes

Seminal vesicle sparing at radical cystectomy provides good oncologic outcomes and helps to preserve urinary continence and sexual function in well-selected patients with bladder cancer, a new stud

Cancer Therapy Advisor
04/02/2021
LuPSMA Outperforms Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer in Phase II Trial

Following disease progression on docetaxel, PSMA-targeted radionuclide therapy reduces the risk of disease progression or death by 37% vs cabazitaxel in men with mCRPC...

The ASCO Post
03/25/2021
Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer

This study seeks to answer the question surrounding the most effective systemic treatments for metastatic castration-sensitive prostate cancer.

JAMA Oncology
Nivolumab: First Adjuvant Immunotherapy to Show Survival Benefit in High-Risk Muscle-Invasive Urothelial Cancer

Adjuvant therapy with nivolumab, an anti–PD-1 immune checkpoint inhibitor, after radical surgery improved disease-free survival in high-risk muscle-invasive urothelial cancer regardless of PD-L1 st

The ASCO Post
03/23/2021
Prostate Cancer Radiotherapy: Increased Biochemical Control and Late Toxicity in Men With Medication Allergies

Given similarities in the mediators of medication allergy and tissue response to radiotherapy, study investigators assess whether outcomes following prostate radiotherapy differ in patients with MA

JNCI Cancer Spectrum
03/22/2021
Can Treatment for Prostate Cancer Affect Smell and Taste?

One in six men being treated for advanced prostate cancer reported experiencing a reduced sense of smell and taste, according to a study published by Alonzi et al. 

The ASCO Post
03/17/2021
18F-Guided PET Radiotracing Boosts Survival After Prostate Cancer Relapse

Adding the 18F-fluciclovine PET radiotracer to help guide radiation treatments for recurrent prostate cancer can improve disease-free survival rates, results from a Phase III study show.

Oncology Times - Latest Articles
Vegetable Intake and the Risk of Bladder Cancer in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) International Study

This research aims to elucidate the association between vegetable intake and bladder cancer risk by conducting a pooled analysis of data from prospective cohort studies.

BMC Medicine
03/09/2021
Radiotherapy of Oligometastatic Prostate Cancer: A Systematic Review

Due to improved imaging sensitivity, the term “oligometastatic” prostate cancer disease is diagnosed more often, leading to an increasing interest in metastasis-directed therapy.

Radiation Oncology
03/09/2021
Cell-Free DNA Concentration and Fragment Size as a Biomarker for Prostate Cancer

This study investigates whether differences in cfDNA concentration and cfDNA fragment size could improve the sensitivity for detecting more advanced and aggressive prostate cancer.

Scientific Reports
03/03/2021
MR-Guided Adaptive Radiotherapy for Bladder Cancer

This article examines the technical challenges of bladder radiotherapy and explore how magnetic resonance guided radiotherapy could be leveraged with the aim of improving bladder cancer patient out

Frontiers in Oncology
02/25/2021
The Prognostic Impact of Tumor Architecture for Upper Urinary Tract Urothelial Carcinoma: A Propensity Score-Weighted Analysis

This study examined the association of tumor architecture with cancer recurrence, metastasis, and cancer-specific survival in patients treated with radical nephroureterectomy for UTUC in Taiwan.

Frontiers in Oncology
02/25/2021

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834